Article View: alt.support.depression
Article #3131Re: GAMMA-OH and trytophan
From: Tom Line
Date: Thu, 25 Feb 1999 00:00
Date: Thu, 25 Feb 1999 00:00
105 lines
5523 bytes
5523 bytes
There's foods very rich in tryptophan. Isn't tryptophan a precursor to
norenephrine that is depleted in the locus corelous in depression in
rats?
Pseudonym@my-dejanews.com wrote:
: There's another way of looking at this. The FDA is going to trash any drug
: that doesn't have a company (and consequently politicians) behind it. They
: explicitly said that one reason they took trytophan off of the market was
: because it was eating into the sales of pharmaceutical companies'
: anti-depressants, and that this wasn't good for psychiatry because
: pharmaceutical companies fund most psychiatric research. If you don't
: believe this check out Shulgin's two books.
: The glass might also be half*full. Now that someone is willing to shell the
: $300 million out that it costs to get a drug approved here in the US, Gamma OH
: will have an advocate, and hence be sold.
: As you might appreciate on my posts about morphine being helpful in cases of
: OCD when even hacking 4 parts of the brain didn't help, it's too bad morphine
: and the other opiates are no longer under patent.
: In article <36d3569c.8475393@news.twics.com>,
: patanie@pasdepubyahoo.com (Claude de Contrecoeur) wrote:
: > Look at the duplicity of the american FDA. They have labelled Gamma-OH
: > a "dangerous" drug and,now,look what they do...
: > This is typical of US commercial maneuvers to attack foreign
: > products:demonisation,until they can catch up.
: >
: > Claude
: >
: > Source: Press Release from Orphan Medical, Inc.
: >
: > PR Contact: John Howell Bullion, Orphan Medical, Inc. , (612) 513-6900
: >
: > Orphan Medical Announces FDA Approval to Initiate
: > A Treatment IND Program
: > for Xyrem (Sodium Oxybate) Oral Solution
: >
: > MINNEAPOLIS, Minnesota � December 17, 1998 � Orphan Medical, Inc.
: > (Nasdaq:
: > ORPH) announced today the approval by the Food and Drug Administration
: > (FDA) of a Treatment IND (Investigational New Drug) for Xyrem (sodium
: > oxybate.Gamma-OH,in French) oral solution. Xyrem is intended to treat
: > narcolepsy, including
: > the reduction of cataplexy. Narcolepsy is a chronic neurologic
: > disorder
: > characterized primarily by unavoidable daytime sleep episodes and
: > cataplexy. Cataplexy, a sudden and often total loss of muscle control,
: > affects the majority of narcolepsy patients. Narcolepsy is estimated
: > to
: > affect at least 125,000 patients in the United States.
: >
: > During the Treatment IND, expected to begin in the first quarter of
: > 1999,
: > the Company will collect additional clinical data necessary for the
: > submission of a new drug application (NDA) to the FDA. The FDA permits
: > an
: > investigational drug to be used under a Treatment IND ---->if there is
: > sufficient evidence of safety and effectiveness and the drug is
: > intended to
: > treat a serious disease.<---- no comment.
: >
: > ``This is a very important milestone for Orphan Medical,'' said John
: > Bullion, CEO of Orphan Medical. ``The initiation of a Treatment IND
: > will
: > enable the company to seek reimbursement for certain development costs
: > while we gather additional clinical data.''
: >
: > Orphan Medical, Inc. is dedicated to patients with inadequately
: > treated or
: > uncommon diseases. To this end, the Company acquires, develops, and
: > markets
: > products of high medical value that address these diseases within
: > selected
: > strategic therapeutic market segments.
: >
: > Orphan Medical's Internet Web Site address is http://www.orphan.com
: >
: -----------== Posted via Deja News, The Discussion Network ==----------
: http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own
--
NOTICE TO SPAMMERS
Pursuant to US Code, Title 47, Chapter 5,
Subchapter II, Sect. 227, any and all
nonsolicited commercial E-mail sent to this
address is subject to a download and archival
fee in the amount of $500.
___________________________
_ | | _
/ )| Tom Line |( \
/ / | AKA FastFingers | \ \
_( (_ | tline@iglou.com | _) )_
(((\ \>|_/->___________________<-\_|</ /)))
(\\\\ \_/ / \ \_/ ////)
\ / \ /
\ _/ \_ /
/ / \ \
/___/ \___\
Technical Details
Message-ID:
<36d57301.0@news.iglou.com>Path:
arc1-ca.pugleaf.net!unknown!not-for-mailReferences:
<36d3569c.8475393@news.twics.com> <7b2qg5$480$1@nnrp1.dejanews.com>Show Full Headers
Complete Article Headers
X-Google-Language: ENGLISH,ASCII X-Google-Thread: 1045ed,5c30a07ea3874225 X-Google-Attributes: gid1045ed,public X-Google-Thread: 10cf66,5c30a07ea3874225 X-Google-Attributes: gid10cf66,public X-Google-Thread: f5f6d,5c30a07ea3874225 X-Google-Attributes: gidf5f6d,public X-Google-Thread: f4552,5c30a07ea3874225 X-Google-Attributes: gidf4552,public From: tline@iglou.com (Tom Line) Subject: Re: GAMMA-OH and trytophan Date: 1999/02/25 Message-ID: <36d57301.0@news.iglou.com> X-Deja-AN: 448391066 X-NNTP-Posting-Host: news-incoming.iglou.com References: <36d3569c.8475393@news.twics.com> <7b2qg5$480$1@nnrp1.dejanews.com> Followup-To: alt.support.depression,sci.med.pharmacy,bionet.neuroscience,fr.soc.politique X-Trace: 25 Feb 1999 10:57:53 -0500, 192.107.41.17 Organization: IgLou Internet Services, Inc. Newsgroups: alt.support.depression,sci.med.pharmacy,bionet.neuroscience,fr.soc.politique